In:
Life, MDPI AG, Vol. 11, No. 2 ( 2021-01-29), p. 102-
Abstract:
Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy for a variety of hematologic diseases. However, this therapeutic platform is limited by an initial period when patients are profoundly immunocompromised. There is gradual immune recovery over time, that varies by transplant platform. Here, we review immune reconstitution after allogeneic HCT with a specific focus on two alternative donor platforms that have dramatically improved access to allogeneic HCT for patients who lack an HLA-matched related or unrelated donor: haploidentical and umbilical cord blood HCT. Despite challenges, interventions are available to mitigate the risks during the immunocompromised period including antimicrobial prophylaxis, modified immune suppression strategies, graft manipulation, and emerging adoptive cell therapies. Such interventions can improve the potential for long-term overall survival after allogeneic HCT.
Type of Medium:
Online Resource
ISSN:
2075-1729
DOI:
10.3390/life11020102
Language:
English
Publisher:
MDPI AG
Publication Date:
2021
detail.hit.zdb_id:
2662250-6
Permalink
